---
schema_version: "secwatch.filing_event.v1"
accession: "0002007919-25-000089"
form_type: "8-K"
ticker: "INBX"
cik: "0002007919"
company_name: "Inhibrx Biosciences, Inc."
filed_at: "2025-10-23T23:59:59+00:00"
generated_at: "2026-05-17T02:35:13.643100+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Ozekibart meets primary endpoint in chondrosarcoma; BLA submission planned Q2 2026

## Summary
- ChonDRAgon study achieved primary endpoint: 52% reduction in risk of progression or death (HR=0.479; p<0.0001); median PFS 5.52 vs 2.66 months.
- Disease control rate 54% (ozekibart) vs 27.5% (placebo); benefit consistent across IDH subgroups.
- CRC expansion cohort (n=26 evaluable): 23% ORR, 92% disease control rate in heavily pretreated patients.
- Ewing sarcoma expansion (n=25 evaluable): 64% ORR, 92% disease control rate; typical standard of care ORR 15-30%.
- One fatal hepatotoxicity event early in study; risk mitigated by excluding severe liver impairment and close monitoring; overall hepatic AEs 11.8% vs 4.5%.

## SEC filing metadata
- accession: 0002007919-25-000089
- form_type: 8-K
- ticker: INBX
- cik: 0002007919
- company_name: Inhibrx Biosciences, Inc.
- filed_at: 2025-10-23T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2007919/000200791925000089/0002007919-25-000089-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2007919/000200791925000089/inhibrx-20251023.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0002007919-25-000089
- JSON: https://secwatch.observer/filing/0002007919-25-000089.json
- Plain text: https://secwatch.observer/filing/0002007919-25-000089.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.